KALA Kala Pharmaceuticals Inc.

3.54
+0.05  (+1%)
Previous Close 3.49
Open 3.52
Price To Book 1.97
Market Cap 120,383,474
Shares 34,006,631
Volume 176,275
Short Ratio
Av. Daily Volume 318,245
Stock charts supplied by TradingView

NewsSee all news

  1. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted a non-statutory stock option to one new employee as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance

  2. Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced August 23, 2018.
INVELTYS
Post‑operative inflammation and pain following cataract surgery
Phase 3 data released January 5, 2017 - both primary symptom endpoints met. Primary sign endpoint missed.
INVELTYS - STRIDE 1
Dry eye disease
CRL issued August 8, 2019. Data from Stride 3 trial due 4Q 2019 are required for resubmission.
KPI‑121 0.25%
Dry eye disease
Phase 3 data due 4Q 2019.
KPI‑121 0.25% STRIDE 3
Dry eye disease

Latest News

  1. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted a non-statutory stock option to one new employee as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance

  2. Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery